Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors
Launched by M.D. ANDERSON CANCER CENTER · Dec 3, 2007
Trial Information
Current as of June 30, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two types of imaging tests—computed tomography urography (CTU) and intravenous urography (IVU)—to see how well they can check for bladder cancer. The study aims to find out if CTU alone could be effective for patients at risk of urothelial tumors, which are types of cancers that affect the lining of the bladder. The trial is currently active but is not recruiting new participants.
To be eligible for this study, patients generally need to be 18 years or older and have been diagnosed with bladder cancer in specific ways, such as having certain types of tumors or having had surgery for bladder cancer. Patients will be invited to participate if they are already scheduled for these imaging tests as part of their regular care. If you decide to join the study, you will undergo both CTU and IVU scans. Participants will need to give their written consent before taking part in the trial. It's important to note that some individuals may not be eligible, such as those with certain kidney issues or allergies to the contrast dye used in the tests.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients who will undergo IVU using digital tomosynthesis and staging abdomino-pelvic CT as part of their routine care will be invited to participate in this study.
- • 2. Patients who have been referred for CTU will also be invited to participate in the study.
- • 3. Such patients will typically
- • 1. Have histologically proven TCC, or
- • 2. Have bladder tumors of Stage ≥ T3, or
- • 3. Had cystectomies for bladder cancer, or
- • 4. Upper tract TCC.
- • 4. \>18 years age.
- • 5. Written informed consent will be obtained from patients.
- Patient exclusion criteria:
- • 1. Elevated serum creatinine of \>2
- • 2. Allergy to intravenous CT contrast media
- • 3. Ureteral stint present or removed within six weeks
- • 4. Women of child bearing potential
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Chaan Ng, MD
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials